Loading…
Lobbying Spend
—
Filings
17
Firms Hired
2
Active Period
2023–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Freedom to Heal Act of 2025
2026 · third_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $20,000
Matched citations: H.R.6434
Freedom to Heal Act of 2025
2026 · third_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $20,000
Matched citations: S.3346
Freedom to Heal Act of 2025
2026 · second_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $20,000
Matched citations: H.R.6434
Freedom to Heal Act of 2025
2026 · second_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $20,000
Matched citations: S.3346
Freedom to Heal Act of 2025
2026 · first_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $20,000
Matched citations: H.R.6434
Freedom to Heal Act of 2025
2026 · first_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $20,000
Matched citations: S.3346
Freedom to Heal Act of 2025
2025 · fourth_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $30,000
Matched citations: H.R.6434
Freedom to Heal Act of 2025
2025 · fourth_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Freedom to Heal Act (H.R.6434/S.3346)
Client expense: — · Firm income: $30,000
Matched citations: S.3346
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · fourth_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $30,000
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · fourth_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $30,000
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · third_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $30,000
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · third_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $30,000
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · second_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $20,000
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · second_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $20,000
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · first_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $10,000
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · first_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $10,000
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · first_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Breakthrough Therapies Act (H.R.1393/S.689), psychedelics research and treatment policy, in general.
Client expense: — · Firm income: —
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · first_quarter · Firm: DB3, LLC (FKA THE DASCHLE GROUP)
Breakthrough Therapies Act (H.R.1393/S.689), psychedelics research and treatment policy, in general.
Client expense: — · Firm income: —
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · first_quarter · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $10,000
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2024 · first_quarter · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $10,000
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2023 · fourth_quarter · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $20,000
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2023 · fourth_quarter · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $20,000
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2023 · third_quarter · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $20,000
Matched citations: H.R.1393
A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2023 · third_quarter · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $20,000
Matched citations: S.689
To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.
2023 · second_quarter · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R.1393/S.689 - Breakthrough Therapies Act; issues related to psychedelic-assisted therapy
Client expense: — · Firm income: $10,000
Matched citations: H.R.1393
Source: Senate LDA